# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Susan B. Anthony (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI014-SYN
- Date: 2026-06-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harold Pemberton, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month heart failure and blood pressure review. **S**

## History of present illness

Miss Anthony returns for her three-month review. She has had no swelling for six weeks and climbs stairs without stopping. Her morning weight has held at 56.0 to 56.4 kg for a month. She has resumed a reduced lecture schedule and walks a mile a day. She has had no dizziness on spironolactone, no breast tenderness, and no muscle cramps. She asks whether she still needs the daily water pill, because it limits her travel. **S**

| Element | Detail |
|---|---|
| Interval change | No edema for six weeks; stairs without stopping |
| Weight diary | Stable at 56.0 to 56.4 kg for a month |
| Medication tolerance | No dizziness, breast tenderness, or cramps on spironolactone |
| Function | Walking a mile a day; reduced lecture schedule |
| Patient goal | Fewer diuretic days so she can travel |
| NYHA class | I to II |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improved; no weight gain |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea, or edema |
| Respiratory | Negative | Breathless only on long climbs |
| Genitourinary | Positive | Urgency on diuretic mornings; no dysuria |
| Neurological | Negative | No dizziness on standing |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |

6 systems reviewed. **S**

## Current medications

- Furosemide 20 mg oral tablet, one tablet by mouth as needed for a weight gain of more than 1 kg in a day or 2 kg in a week **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/74 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 56.2 kg; BMI 20.6 kg/m². All vital signs are synthetic.

NT-proBNP: 720 pg/mL (high); Sodium: 137 mmol/L; Potassium: 4.5 mmol/L; Creatinine: 0.92 mg/dL; eGFR: 61 mL/min/1.73 m²; Glucose: 95 mg/dL; Magnesium: 2 mg/dL; KCCQ-12 overall summary: 70; PHQ-2: 0. All results are synthetic.

## Change since baseline

- NT-proBNP: 1650 pg/mL (high) at baseline, 720 pg/mL (high) at this visit **S**
- Sodium: 138 mmol/L at baseline, 137 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 0.88 mg/dL at baseline, 0.92 mg/dL at this visit **S**
- eGFR: 64 mL/min/1.73 m² at baseline, 61 mL/min/1.73 m² at this visit **S**
- Glucose: 96 mg/dL at baseline, 95 mg/dL at this visit **S**
- Magnesium: 2 mg/dL at baseline, 2 mg/dL at this visit **S**
- KCCQ-12 overall summary: 52 at baseline, 70 at this visit **S**
- PHQ-2: 0 at baseline, 0 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, energetic |
| Neck | Jugular venous pressure 6 cm |
| Lungs | Clear |
| Heart | Regular rhythm; soft S4 |
| Extremities | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Heart failure with preserved ejection fraction, euvolemic** (I50.32). Dry weight 56 kg reached, with no congestion on examination. NT-proBNP has fallen from 1650 to 720 pg/mL and the KCCQ-12 has risen from 52 to 70. Potassium 4.5 on spironolactone. **S**
   - Change furosemide to as needed, for a weight gain of more than 1 kg in a day or 2 kg in a week.
   - Continue empagliflozin and spironolactone.
   - Written travel plan: weigh each morning on the road and carry furosemide.
   - Basic metabolic panel at the six-month review.
2. **Hypertensive heart disease** (I11.0). Blood pressure 132/74 mmHg, nearly at the 130/80 target. **S**
   - No change; recheck at the six-month review.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel with magnesium | 1 to 2 weeks after starting or changing therapy; every 3 to 6 months when stable | Completed today | Potassium 4.5, eGFR 61. This is the first panel since spironolactone started three months ago |
| Laboratory | Basic metabolic panel 1 to 2 weeks after starting spironolactone | Once, after starting a mineralocorticoid antagonist | Deferred | Not drawn in the two-week window, a deviation from the protocol. Today's potassium and kidney function are normal, so no harm resulted; the reminder is now in her chart |
| Laboratory | NT-proBNP | Selectively in outpatient follow-up | Completed today | 720 pg/mL, down from 1650; informs decongestion, not used to titrate therapy |
| Examination | Blood pressure, heart rate, weight, jugular venous pressure, edema, lungs | Every visit | Completed today | Euvolemic at 56.2 kg |
| Survey | NYHA functional class | Every visit | Completed today | Class I to II |
| Survey | KCCQ-12 | Every 3 to 6 months | Completed today | 70, up 18 points from baseline |
| Survey | Depression screen (PHQ-2) | Periodically | Completed today | Score 0 |
| Imaging | Echocardiogram | Only with unexplained clinical change | Not indicated | Improving as expected; routine repeat imaging is not recommended |
| Referral | Cardiac rehabilitation | If exercise tolerance plateaus | Not indicated | Exercise tolerance still improving with daily walking |
| Self-management | Daily weight diary and travel plan | Every visit | Completed today | Travel weight plan written today |

## Goal progress

- Reach euvolemia with no ankle edema and a stable dry weight within three months. Outcome by 2026-06-29: Dry weight 56 kg; furosemide changed to as-needed use. **S**
- Improve the KCCQ-12 overall summary score by at least 15 points by the three-month review. Outcome by 2026-06-29: KCCQ-12 rose from 52 to 70. **S**
- Lower blood pressure below 130/80 by the six-month review without orthostatic symptoms. In progress; target 2026-09-28. **S**
- Resume a full speaking and travel schedule by the six-month review. In progress; target 2026-09-28. **S**

## Medication changes

- Stopped: Furosemide 20 mg oral tablet, one tablet by mouth daily **S**
- Started: Furosemide 20 mg oral tablet, one tablet by mouth as needed for a weight gain of more than 1 kg in a day or 2 kg in a week **S**

## Guideline basis

- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America
- 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023), American College of Cardiology
- CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026), Aether Forge

## Follow-up

- Six-month heart failure review with a basic metabolic panel and KCCQ-12. **S**
- Next scheduled visit 2026-09-28: six-month heart failure review. **S**
